Autopsy report · NCT05096949

Implementing Cabenuva in Arkansas HIV Programs

“Insufficient enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 1 year 10 months before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

University of Arkansas

Sponsor type

University, hospital or other

Conditions

HIV-1-infection; Medication Adherence; Satisfaction, Patient

Interventions

Home visit delivery strategy

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• Treatment Prior to Injection and Biopsy of the Vulva
  “Not enough enrollment” (90% match in meaning)
• Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
  “Lack of enrollment” (88% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.